| abstract |
Disclosed is the use of a combination of: a compound of formula (1), interferon alpha, and ribavirin for the manufacture of a medicament for the treatment of hepatitis C virus (HCV) infection or alleviating one or more symptoms thereof. The compound of formula (1) is a selective and potent inhibitor of the HCV NS3 serine protease, and comprised quinoline, thiophene and cyclopropane moieties. |